Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Generalised anxiety disorder (GAD) is a chronic and pervasive condition that generates high levels of psychological stress, and it is difficult to treat in the long term. Current pharmacotherapeutic options for GAD are in some cases only modestly effective, and may elicit undesirable side effects. Through targeted actions on the gamma-aminobutyric acid (GABA) pathway, the South Pacific medicinal plant kava (Piper methysticum) is a non-addictive, non-hypnotic anxiolytic with the potential to treat GAD. The evidence for the efficacy of kava for treating anxiety has been affirmed through clinical trials and meta-analyses. Recent research has also served to lessen safety concerns regarding the use of kava due to hepatotoxic risk, which is reflected in a recent German court overturning the previous kava ban in that country (which may in turn influence a reinstatement by the European Union). The aim of current research is to assess the efficacy of an 'aqueous noble cultivar rootstock extract' of kava in GAD in a larger longer term study. In addition, we plan to investigate the pharmacogenomic influence of GABA transporters on response, effects of kava on gene expression, and for the first time, the neurobiological correlates of treatment response via functional and metabolic imaging. METHODS/DESIGN: This clinical trial is funded by the Australian National Health and Medical Research Council (APP1063383) and co-funded by MediHerb (Integria Healthcare (Australia) Pty. Ltd). The study is a phase III, multi-site, two-arm, 18-week, randomised, double-blind, placebo-controlled study using an aqueous extract of noble kava cultivar (standardised to 240 mg of kavalactones per day) versus matching placebo in 210 currently anxious participants with diagnosed GAD who are non-medicated. The study takes place at two sites: the Centre for Human Psychopharmacology (Swinburne University of Technology), Hawthorn, Melbourne, Australia; and the Academic Discipline of Psychiatry (The University of Queensland) based at the Royal Brisbane and Women's Hospital, Herston, Brisbane, Australia. Written informed consent will be obtained from each participant prior to commencement in the study. The primary outcome is the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A). The secondary outcomes involve a range of scales that assess affective disorder symptoms and quality of life outcomes, in addition to the study of mediating biomarkers of response (assessed via genomics and neuroimaging). DISCUSSION: If this study demonstrates positive findings in support of the superiority of kava over placebo in the treatment of GAD, and also is shown to be safe, then this plant-medicine can be considered a 'first-line' therapy for GAD. Genomic and neuroimaging data may reveal clinical response patterns and provide more evidence of the neurobiological activity of the plant extract. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov: NCT02219880 Date: 13 August 2014:.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · cited 1×
“Study protocol and processes have been developed in line with Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines [66].”
MethodSkevington, S. M., Lotfy, M., & O'Connell, K. A. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018486.91360.00 · Cited by 4,686 · cited 1×
“3) Kava will be superior to placebo on health-related quality of life measured using The World Health Organization Quality of Life - BREF (WHOQOLBREF) [42], the Social Re-adjustment Rating Scale [43], and the Kessler Psychological Distress Scale [44].”
MethodThe size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
Lecrubier, Y., Sheehan, D., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., Janavs, J., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83296-8 · Cited by 3,513 · cited 1×
“0 [46]), and is sensitive to change [47, 48].”
BackgroundParadoxical effects of thought suppression.
Wegner, D. M., Schneider, D. J., Carter, S. R., & White, T. L. (1987) · Journal of Personality and Social Psychology · doi:10.1037//0022-3514.53.1.5 · Cited by 2,127 · cited 1×
“The ACC is thought to mediate affective and cognitive aspects of phenomena such as sadness recall, selective attention, loss, error and reward, suppression of negative emotion or cognitions, and autonomic processes that underpin anxiety states [71–79].”
BackgroundGlobal prevalence of anxiety disorders: a systematic review and meta-regression
Baxter, A. J., Scott, K. M., Vos, T., & Whiteford, H. A. (2013) · Psychological Medicine · doi:10.1017/s003329171200147x · Cited by 1,537
Human cingulate cortex and autonomic control: converging neuroimaging and clinical evidence
Critchley, H. D., Mathias, C. J., Josephs, O., O’Doherty, J., Zanini, S., Dewar, B., Cipolotti, L., Shallice, T., & Dolan, R. J. (2003) · Brain · doi:10.1093/brain/awg216 · Cited by 1,201 · cited 1×
“The ACC is thought to mediate affective and cognitive aspects of phenomena such as sadness recall, selective attention, loss, error and reward, suppression of negative emotion or cognitions, and autonomic processes that underpin anxiety states [71–79].”
BackgroundFunctional neuroanatomy of emotions: A meta-analysis
MURPHY, F. C., NIMMO-SMITH, I., & LAWRENCE, A. D. (2003) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/cabn.3.3.207 · Cited by 1,135
Maier, W., Buller, R., Philipp, M., & Heuser, I. (1988) · Journal of Affective Disorders · doi:10.1016/0165-0327(88)90072-9 · Cited by 1,044 · cited 1×
“0 [46]), and is sensitive to change [47, 48].”
BackgroundPsychometric properties of the Penn State Worry Questionnaire in a clinical anxiety disorders sample
Brown, T. A., Antony, M. M., & Barlow, D. H. (1992) · Behaviour Research and Therapy · doi:10.1016/0005-7967(92)90093-v · Cited by 812
Cited by
Salehi, B., Zakaria, Z. A., Gyawali, R., Ibrahim, S. A., Rajkovic, J., Shinwari, Z. K., Khan, T., Sharifi-Rad, J., Ozleyen, A., Turkdonmez, E., et al. (2019) · Molecules · doi:10.3390/molecules24071364 · Cited by 523
GABA-modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence
Savage, K., Firth, J., Stough, C., & Sarris, J. (2018) · Phytotherapy Research · doi:10.1002/ptr.5940 · Cited by 131
Self-citationHerbal hepatotoxicity: Clinical characteristics and listing compilation
Frenzel, C., & Teschke, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050588 · Cited by 122
Self-citationChua, H. C., Christensen, E. T. H., Hoestgaard-Jensen, K., Hartiadi, L. Y., Ramzan, I., Jensen, A. A., Absalom, N. L., & Chebib, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157700 · Cited by 87
Trkulja, V., & Barić, H. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9705-0_22 · Cited by 28
Metadata
- Authors
- Savage, K. M., Stough, C. K., Byrne, G. J., Scholey, A., Bousman, C., Murphy, J., Macdonald, P., Suo, C., Hughes, M., Thomas, S., Teschke, R., Xing, C., & Sarris, J.
- Venue
- Trials
- Published
- 2015-11-02
- Volume
- 16
- Issue
- 1
- Pages
- 493-493
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2112191686
- Cited by
- 41
- References
- 20
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. https://app.cochat.ai/papers/10.1186/s13063-015-0986-5
- The paper
- Savage, K. M., Stough, C. K., Byrne, G. J., Scholey, A., Bousman, C., Murphy, J., Macdonald, P., Suo, C., Hughes, M., Thomas, S., Teschke, R., Xing, C., & Sarris, J. (2015). Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. Trials. https://doi.org/10.1186/s13063-015-0986-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.